Overview

Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A

Status:
NOT_YET_RECRUITING

Trial end date:
2030-11-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, phase 2, randomized trial to evaluate the efficacy and safety of obinutuzumab with CHOP versus obinutuzumab with bendamustine in treatment-nave follicular lymphoma (Grade 3A) patients.

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Bendamustine Hydrochloride
obinutuzumab